Candel Therapeutics’ Promising CAN-2409 Program Drives Buy Rating Amid Positive Phase 3 Results and Expert Endorsements
I'm PortAI, I can summarize articles.
Analyst Oliver McCammon of LifeSci Capital maintains a Buy rating on Candel Therapeutics, citing promising Phase 3 results of CAN-2409 for prostate cancer. The treatment showed a 30% reduction in disease recurrence. Positive endorsements from key opinion leaders and strategic focus support the optimistic view. H.C. Wainwright also reiterated a Buy rating with a $23.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments